A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Prior treatment

• Prior allogeneic stem cell transplant.
• Use of prohibited medications within the washout period defined in the protocol.

Other illness

• Any condition that confounds the ability to interpret data from the study.
• Central nervous system (CNS)-only involvement by malignancy. (Note: participants with secondary CNS involvement are allowed.)
• Other comorbid conditions defined in the protocol.

Other

• Presence of clinically significant CNS pathology.

• Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
• Must have met the following criteria for prior treatment:
  • Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor [CAR] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator.
  • Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator.
  • Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies.
• Measurable disease on screening evaluations.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ function.
• Life expectancy of ≥12 weeks.